Johnson & Johnson added new warnings to its schizophrenia drug, Haldol, about the potential risk of death and of dangerous heart conditions observed in some patients. The FDA said new labeling on the drug will note that ailments, including QT prolongation, a disorder of the heart's electrical system that can lead to a life-threatening condition, have been observed in post-marketing studies. The drug is also sold generically under the name haloperidol. Several other drugs for schizophrenia, including a much newer J&J drug including Invega, have warnings about the risk of the serious cardiac effect. The FDA, in a posting on its web site, said the new labeling comes after a number of case reports of sudden death and QT prolongation in patients treated with the drug.
Haldol Legal Help
If you or a loved one has suffered damages in this drug case, please click the link below to send your complaint to a lawyer to evaluate your claim at no cost or obligation.Last updated on Sep-18-07